Prediction of Mortality in Clinical Practice for Medicare Patients Undergoing Defibrillator Implantation for Primary Prevention of Sudden Cardiac Death  by Bilchick, Kenneth C. et al.
Journal of the American College of Cardiology Vol. 60, No. 17, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Heart Rhythm Disorders
Prediction of Mortality in Clinical Practice for
Medicare Patients Undergoing Defibrillator
Implantation for Primary Prevention of
Sudden Cardiac Death
Kenneth C. Bilchick, MD, MS,* George J. Stukenborg, PHD, MA,† Sandeep Kamath, MD,*
Alan Cheng, MD‡
Charlottesville, Virginia; and Baltimore, Maryland
Objectives The aim of this study was to derive and validate a practical risk model to predict death within 4 years of primary
prevention implantable cardioverter-defibrillator (ICD) implantation.
Background ICDs for the primary prevention of sudden cardiac death improve survival, but recent data suggest that a patient
subset with high mortality and minimal ICD benefit may be identified.
Methods Data from a development cohort (n  17,991) and validation cohort (n  27,893) of Medicare beneficiaries receiving
primary prevention ICDs from 2005 to 2007 were merged with outcomes data through mid-2010 to construct and
validate complete and abbreviated risk models for all-cause mortality using Cox proportional hazards regression.
Results Over a median follow-up period of 4 years, 6,741 (37.5%) development and 8,595 (30.8%) validation cohort patients
died. The abbreviated model was based on 7 clinically relevant predictors of mortality identified from complete model
results, referred to as the “SHOCKED” predictors: 75 years of age or older (hazard ratio [HR]: 1.70; 95% confidence
interval [CI]: 1.62 to 1.79), heart failure (New York Heart Association functional class III) (HR: 1.35; 95% CI: 1.29 to
1.42), out of rhythm because of atrial fibrillation (HR: 1.26; 95% CI: 1.19 to 1.33), chronic obstructive pulmonary
disease (HR: 1.70; 95% CI: 1.61 to 1.80), kidney disease (chronic) (HR: 2.33; 95% CI: 2.20 to 2.47), ejection fraction
(left ventricular)  20% (HR: 1.26; 95% CI: 1.20 to 1.33), and diabetes mellitus (HR: 1.43; 95% CI: 1.36 to 1.50). This
model had C-statistics of 0.75 (95% CI: 0.75 to 0.76) and 0.74 (95% CI: 0.74 to 0.75) in the development and valida-
tion cohorts, respectively. Validation patients in the highest risk decile on the basis of the SHOCKED predictors had a
65% 3-year mortality rate. A nomogram is provided for survival probabilities 1 to 4 years after ICD implantation.
Conclusions This useful model, based on more than 45,000 primary prevention ICD patients, accurately identifies pa-
tients at highest risk for death after device implantation and may significantly influence clinical decision
making. (J Am Coll Cardiol 2012;60:1647–55) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.028r
aImplantable cardioverter-defibrillators (ICDs) have become
the cornerstone in the primary prevention of sudden cardiac
death (SCD) for patients with left ventricular systolic dysfunc-
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accepted July 17, 2012.tion and heart failure (1–4). Although the absolute risk
reduction for total mortality is approximately 7.2% over 5 years
(3), only a minority of ICD recipients in these clinical trials
eceived therapies for ventricular tachyarrhythmias (5). In
ddition, many patients are at risk for competing modes of
See page 1656
death or may die soon after ICD implantation (6). Hence, there
are certain subsets of ICD recipients who will never benefit from
ICDs. On the basis of these and other factors (7,8), there is
a need to accurately estimate a patient’s risk for death from
competing causes as part of the treatment decision-making
process. Although predictors of mortality based on clinical
trials have been identified (6,9,10), their applicability to
patients in clinical practice remains unclear.
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jor clinical trials have not shown
statistically significant survival
benefits for patients in the high-
est 10% to 20% of predicted risk
after ICD implantation (6,10).
Specifically, in the SCD-HeFT
(Sudden Cardiac Death in Heart
Failure Trial) model, patients in
the highest quintile of risk had a
2-year mortality rate of 30% and
did not have any statistically sig-
nificant benefit as a result of ICD
implantation (6). In the MADIT
II (Multicenter Automatic Defi-
brillator Implantation Trial II)
model, neither the 14% of ICD
patients with 3 or more risk fac-
tors nor the 5% of ICD patients
in the prespecified very high risk group had a statistically
significant survival benefit from ICD implantation (10). In
this combined group of patients with 3 or more risk factors
or very high risk status (19% of ICD patients overall), 33%
died during the first 2 years. These data suggest that early
predicted mortality rates above a certain threshold identify
high-risk subgroups unlikely to benefit from ICDs in
clinical practice. Because a risk model based on large
numbers of patients receiving ICDs in clinical practice is
lacking, we sought to derive and validate a mortality risk
assessment model for use in clinical practice using 2 separate
registries of Medicare patients undergoing primary preven-
tion ICD implantation. The aim was to identify a subgroup
of patients at greatest risk for death during the first several
years after ICD implantation.
Methods
Cohort selection. In 2005, the Centers for Medicare and
Medicaid Services (CMS) expanded Medicare coverage of
ICDs and required all hospitals to submit patient-level data
to an ICD registry as a criterion of coverage. Medicare
beneficiaries represent the vast majority of older patients in
the United States with primary prevention ICD implants.
Two distinct Medicare cohorts were identified and used
separately for the development and validation of a model for
estimating mortality risk after ICD implantation. The
model development cohort was obtained using the ICD
registry maintained by the Iowa Foundation for Medical
Care for Medicare beneficiaries with ICD implantations
occurring between January 2005 and April 2006. The
validation cohort was obtained by identifying Medicare
patients with primary prevention ICD implants (single-or
dual-chamber) from 2005 to 2007 from the American
College of Cardiology’s National Cardiovascular Data Reg-
istry ICD Registry (excluding patients from the Iowa
Abbreviations
and Acronyms
CI  confidence interval
CKD  chronic kidney
disease
CMS  Centers for
Medicare and Medicaid
Services
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
SCD  sudden cardiac
deathFoundation for Medical Care registry) with the standardInternational Classification of Diseases, Ninth Revision,
Clinical Modification procedure code (37.94) for the initial
system implantation of an ICD, as documented in the
Medicare utilization files. All patients in the cohort were
Medicare eligible and are highly representative of patients
with ICD implants, as patients with Medicare coverage
make up the largest proportion of patients receiving ICDs
in the United States.
All patients in the analysis met 1 of the following
standard criteria for primary prevention ICD implantation
(11): 1) symptomatic heart failure for at least 3 months with
left ventricular ejection fraction (LVEF) 35% or lower (3),
2) prior myocardial infarction with LVEF 30% or lower (2),
or 3) nonsustained ventricular tachycardia because of prior
myocardial infarction with LVEF  40% and inducible
ventricular fibrillation or sustained ventricular tachycardia
on electrophysiological study (4). Exclusion criteria were:
1) New York Heart Association (NYHA) functional class
IV; 2) NYHA functional class I in patients with nonisch-
emic cardiomyopathy; 3) percutaneous coronary interven-
tion or coronary artery bypass grafting within 3 months of
ICD implantation; and 4) myocardial infarction within 40
days of ICD implantation.
Determination of mortality and matching process. To
determine mortality after ICD implantation, registry data
were merged with Medicare data on post-implantation
survival obtained from eligibility and hospital claims and
utilization records by CMS. The development cohort was
matched on health insurance claim number, date of birth,
and sex, and only patients matching in all fields were
included in the analysis (Table 1). The validation cohort was
matched on Social Security number, date of birth, and sex.
In the same way, only patients matching in all 3 fields were
included in the analysis. As a result, the matches between
the ICD databases and CMS utilization data are both
expected to be completely accurate, because the probability
of a match error for patients matched on all 3 criteria is
exceedingly small. Analyses of all data were approved by the
CMS Privacy Board.
Statistical analysis. MODEL CONSTRUCTION. Multivariate
Cox proportional hazards regression analysis was used to
estimate the probability of death over the available period of
follow-up for each ICD patient in the development cohort.
The statistical model expressed this probability as a function
of patient-specific values for a series of pre-specified clinical
and demographic characteristics. The following variables
were included in the model: age, LVEF, QRS duration, sex,
atrial fibrillation, NYHA functional class, duration of heart
failure, diabetes mellitus, chronic obstructive pulmonary
disease, chronic kidney disease (CKD), depression, cancer
(including breast, colon, and prostate cancer), previous
myocardial infarction, prior coronary artery bypass grafting,
prior percutaneous coronary intervention, bundle branch
block configuration, systolic blood pressure, diastolic blood
pressure, heart rate, and medication use (including
digoxin, beta-blockers, angiotensin-converting enzyme
ew York
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and warfarin). These patient characteristics were deter-
mined using both data from the ICD Registry databases
and International Classification of Diseases, Ninth Re-
vision, Clinical Modification codes from CMS utilization
data (12).
The complete model served as a reference standard for an
abbreviated model designed to be a more practical subset for
estimating patient mortality risk. Seven covariates were
selected for use in the abbreviated model on the basis of the
relative magnitudes of their contributions to model perfor-
mance (measured using the Wald chi-square test statistic),
relative frequency of occurrence, and clinical relevance. We
also sought to identify demographic and clinical character-
istics of the patients for the abbreviated model rather than
covariates based on therapeutic decisions (i.e., medication
use). Multivariable Cox proportional hazards regression
analysis was used to estimate the probability of survival
using the abbreviated model. A nomogram was then con-
structed on the basis of the abbreviated model results. Data
management and multivariable Cox proportional hazards
regression analyses were conducted using SAS version 9.2
(SAS, Cary, North Carolina). The nomogram and calibra-
tion plots produced for the abbreviated model were devel-
oped using R statistical software version 2.13 and the Hmisc
package (R Foundation for Statistical Computing, Vienna,
Austria).
CALIBRATION, DISCRIMINATION, AND VALIDATIONOF RISK
MODELS. The calibration of the abbreviated model was
assessed by measuring the Pearson correlation coefficient
obtained between survival probabilities produced by the
complete model and those produced by the abbreviated
model for the same patients in the development cohort. The
Hosmer-Lemeshow test statistic was also calculated for the
abbreviated model in the validation population using logis-
tic regression analysis to assess the probability of mortality at
any point in time for patients with 2, 3, and 4 years of
Composition of Derivation and Validation CohortTable 1 Composition of Derivation and Valid
Initial single-chamber or dual-chamber ICD implantation
for primary prevention of SCD, matched on HIC/SSN
Matching date of birth and sex
LVEF 40%
NYHA functional class I–III HF (excluding class IV)
No PCI or CABG within 3 months
No MI within 40 days
Fulfills remaining criteria for implantation*
Final cohort total
*LVEF 35% and NYHA class II or III (at least 3 months); LVEF 30%
ventricular tachycardia or ventricular fibrillation on electrophysiologica
CABG  coronary artery bypass grafting; HF  heart failure; HIC 
left ventricular ejection fraction; MImyocardial infarction; NYHA N
sudden cardiac death; SSN  Social Security number.follow-up. Each logistic regression model included the samecovariates used in the proportional hazards regression
model. Each population was stratified into deciles with
similar mortality risk. Observed and expected deaths were
then calculated for each decile.
The discrimination obtained by the complete model and
abbreviated model in the development cohort was evaluated
using the C-statistic from the Cox proportional hazards
model (13–15). Validation of the C-statistic obtained by the
abbreviated model equation was accomplished by applying
the developed model equation with fixed parameter coeffi-
cients to data for patients in the validation cohort.
OTHER STATISTICAL ANALYSIS. Correlations are reported
on the basis of the Pearson correlation coefficient and
significance level. Standard chi-square tests were used in
comparisons of categorical values between groups, while
Student t tests were used for comparisons of continuous
variables between groups. Wald (type 3) chi-square statistics
are reported for each variable used in the Cox proportional
hazards analysis to provide measures of the relative predic-
tive strength of the each variable.
Results
Baseline characteristics of the development and validation
cohorts. As shown in Table 1, we identified 17,991 pa-
tients for the development cohort (based on the 94% of
patients matched on health insurance claim numbers to
Medicare data on post-implantation survival) and 27,893
patients in the validation cohort (based on the 97% of
patients matched on Social Security number). The baseline
characteristics at the time of ICD implantation are shown
for both the development and validation cohorts in Table 2.
The overall median age for all patients was 72.5 years.
Patients in both cohorts were primarily men, and more than
half of the patients in both groups had prior myocardial
infarctions. The differences in the distributions of demo-
graphic and clinical characteristics between the development
Cohorts
Derivation Cohort Validation Cohort
cluded Excluded Included Excluded
3,405 42,903
1,597 1,808 39,687 3,216
0,918 679 37,732 1,955
0,206 712 36,498 1,234
9,070 1,136 33,552 2,946
8,869 201 31,966 1,586
7,991 878 27,893 4,073
7,991 27,893
or MI; and LVEF 40%, MI, nonsustained ventricular tachycardia, and
.
insurance claim; ICD  implantable cardioverter-defibrillator; LVEF 
Heart Association; PCI percutaneous coronary intervention; SCDsation
In
2
2
2
2
1
1
1
1
and pri
l study
healthand validation cohorts were often statistically significant,
blocker
able 1.
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most cases. The statistical significance of these differences
reflects the large number of cases included in each cohort. A
majority of patients in the development cohort were on
appropriate heart failure medications.
In the development cohort of 17,991 patients, 6,741
Demographic and Clinical CharacteristicsTable 2 Demographic and Clinical Characte
Variable
De
Age (yrs)
55 1
55–64 2
65–74 7
75–84 6
85
Female 4
Race
African American 1
Caucasian 15
Other 1
Hispanic ethnicity
QRS duration (ms)
120 10
120–149 4
150 3
Atrial fibrillation 4
LVEF  20% 5
NYHA functional class
I 1
II 9
III 7
Chronic obstructive pulmonary disease 3
Diabetes mellitus 6
Chronic kidney disease 2
Prior myocardial infarction 10
Prior coronary artery bypass grafting 7
Prior percutaneous coronary intervention 2
History of cancer
Breast cancer
Colon cancer
Prostate cancer
Depression 1
Bundle branch block*
None 10
LBBB 3
IVCD 2
RBBB 1
Medication use*
Digoxin 5
Beta-blockers 14
ACE inhibitors/ARBs 13
Diuretic agents 11
Amiodarone 1
Warfarin 4
Values are n (%). *Bundle branch block configuration and medication
ACE angiotensin-converting enzyme; ARB angiotensin receptor
block; RBBB  right bundle branch block. Other abbreviations as in Tpatients (37.5%) died during a median follow-up period of4.4 years (interquartile range: 4.2 to 4.6 years). In the
validation cohort, 8,595 of the 27,893 patients (30.8%) died
during a median follow-up period of 3.6 years (interquartile
range: 3.1 to 4.0 years).
Identification of predictive covariates. Table 3 presents
results for the Cox proportional hazards regression model
s
ent
t
Validation
Cohort p Value
0.001
.3) 2,058 (7.4)
1.8) 3,176 (11.4)
3.1) 11,732 (42.1)
4.7) 9,622 (34.5)
.1) 1,305 (4.7)
2.5) 6,955 (24.9) 0.001
0.001
0.3) 3,454 (12.4)
3.7) 23,105 (82.8)
.0) 1,334 (4.8)
.8) 1,439 (5.2) 0.001
0.001
9.0) 17,391 (62.4)
2.2) 5,842 (20.9)
8.8) 4,660 (16.7)
2.7) 7,805 (28.0) 0.001
1.6) 8,723 (31.3) 0.44
0.001
.8) 2,153 (7.7)
1.0) 14,267 (51.2)
0.2) 11,473 (41.1)
8.4) 7,157 (25.7) 0.001
3.6) 12,288 (44.1) 0.001
5.2) 7,757 (27.8) 0.001
8.5) 17,683 (63.4) 0.001
4.0) 11,975 (42.9) 0.03
6.4) 9,398 (33.8) 0.001
.5) 245 (0.9) 0.001
.6) 222 (0.8) 0.002
.9) 1,125 (4.0) 0.001
.8) 2,689 (9.6) 0.001
9.0)
8.7)
5.8)
.5)
2.2)
9.5)
4.1)
5.1)
.8)
7.5)
re available only for the development cohort.
; IVCD intraventricular conduction delay; LBBB left bundle branchristic
velopm
Cohor
,140 (6
,115 (1
,747 (4
,247 (3
742 (4
,056 (2
,851 (1
,055 (8
,085 (6
680 (3
,617 (5
,000 (2
,374 (1
,076 (2
,688 (3
,592 (8
,173 (5
,226 (4
,302 (1
,053 (3
,729 (1
,521 (5
,913 (4
,950 (1
93 (0
99 (0
529 (2
,230 (6
,617 (5
,362 (1
,846 (1
,166 (6
,789 (3
,298 (7
,330 (7
,713 (6
,590 (8
,952 (2
use weestimated in the development cohort using all of the
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Covariate HR 95% CI p Value Wald Chi-Square
Age (yrs)* 663.0
55 1.00
55–64 1.20 1.05–1.38 0.008
65–74 1.43 1.27–1.62 0.001
75–84 2.18 1.93–2.47 0.001
85 4.03 3.47–4.68 0.001
Sex 19.2
Male 1.00
Female 0.87 0.82–0.93 0.001
Race 28.0
Caucasian 1.00
African American 1.23 1.14–1.34 0.001
Other 1.10 0.97–1.25 0.05
QRS duration (ms) 19.7
120 1.00
120–149 1.17 1.09–1.25 0.001
150 1.16 1.06–1.25 0.001
Bundle branch block 11.6
None 1.00
LBBB 0.88 0.81–0.95 0.001
IVCD 0.95 0.86–1.05 0.31
RBBB 1.05 0.95–1.17 0.35
Atrial fibrillation* 1.17 1.10–1.25 0.001 23.7
LVEF* 65.2
25% 1.00
21%–25% 1.08 1.02–1.15 0.01
20% 1.27 1.19–1.34 0.001
NYHA functional class* 117.1
I 1.00
II 1.05 0.95–1.16 0.31
III 1.37 1.24–1.51 0.001
Duration of HF (months) 1.001 1.000–1.002 0.25 1.3
Diabetes mellitus* 1.41 1.34–1.49 0.001 175.1
Chronic obstructive pulmonary disease* 1.63 1.54–1.73 0.001 293.0
Chronic kidney disease* 2.28 2.15–2.41 0.001 764.4
Prior myocardial infarction 1.00 0.95–1.05 0.66 0.2
Prior coronary artery bypass grafting 1.06 1.00–1.11 0.04 4.5
Systolic BP (10 mm Hg) 0.97 0.96–0.99 0.001 17.2
Diastolic BP (10 mm Hg) 0.98 0.95–0.99 0.03 4.8
Heart rate (10 beats/min) 1.04 1.03–1.05 0.001 61.5
Medication use
Digoxin 1.14 1.08–1.20 0.001 24.8
Beta-blockers 0.87 0.82–0.92 0.001 23.8
ACE inhibitors 0.84 0.80–0.89 0.001 40.0
Diuretic agents 1.25 1.18–1.32 0.001 62.7
Amiodarone 1.05 0.97–1.14 0.20 1.7
Warfarin 0.99 0.94–1.06 0.95 0.01
Cancer
Breast cancer 1.20 0.88–1.64 0.25 1.3
Colon cancer 1.02 0.76–1.37 0.85 0.02
Prostate cancer 1.04 0.91–1.18 1.00 0.32
Depression 1.31 1.20–1.43 0.001 36.5*Covariate used in the nomogram-based score and abbreviated model.
BP  blood pressure; CI  confidence interval; HF  heart failure; HR  hazard ratio; other abbreviations as in Tables 1 and 2.
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shown in Table 4, 7 of these clinical and demographic
haracteristics were selected for use as covariates in an
bbreviated risk model: CKD (hazard ratio [HR]: 2.33; 95%
onfidence interval [CI]: 2.20 to 2.47), age 75 years (HR:
1.70; 95% CI 1.62 to 1.79), chronic obstructive pulmonary
disease (HR: 1.70; 95% CI: 1.61 to 1.80), diabetes mellitus
(HR: 1.43; 95% CI: 1.36 to 1.50), NYHA class III (HR:
1.35; 95% CI: 1.29 to 1.42), atrial fibrillation (HR: 1.26;
95% CI: 1.19 to 1.33), and LVEF 20% (HR: 1.26; 95%
CI: 1.20 to 1.33). These 7 covariates were selected for use in
the abbreviated model because they had the largest inde-
pendent contributions to the predictive performance of the
model, occurred frequently, and had strong clinical rele-
vance. Of note, CKD had the largest independent contri-
bution to the predictive performance of the model (Wald
chi-square statistic  831.7).
Figure 1 Hosmer-Lemeshow Test Statistics and Model Calibrat
The relationship between observed and expected numbers of deaths as a percent
follow-up after implantable cardioverter-defibrillator implantation is shown. The line
along with a dashed line identifying the ideal association. HL  Hosmer-Lemeshow
HRs and CIs for Abbreviated Model CovariatesTable 4 HRs and CIs for Abbreviated Model
Covariate HR
Chronic kidney disease 2.33
Age (yrs)
75 1.00
75 1.70
Chronic obstructive pulmonary disease 1.70
Diabetes mellitus 1.43
NYHA functional class
I or II 1.00
III 1.35
LVEF
20% 1.00
20% 1.26
Atrial fibrillation 1.26
Abbreviations as in Tables 1 and 3.Calibration, discrimination, and validation. An excellent
correlation was obtained between the survival probabilities
determined using the complete and abbreviated models for
each patient (r  0.89, p  0.001). In the development
ohort, the C-statistic obtained for the abbreviated model
as 0.75 (95% CI: 0.75 to 0.76). The C-statistic obtained
or the complete model was 0.73 (95% CI: 0.72 to 0.74).
oth models were well calibrated in this cohort with nearly
quivalent results obtained by the complete and abbreviated
odels. In the validation cohort, the abbreviated model
btained a C-statistic of 0.74 (95% CI: 0.74 to 0.75), which
emonstrated that there was almost no attenuation of the
odel performance obtained in the development cohort.
Logistic regression analysis was used to assess the prob-
bility of mortality at any point in time for groups of
atients in the study population with 2, 3, and 4 years of
vailable follow-up. Figure 1 presents plots of the relation-
lots
group deciles for events during 2 years (A), 3 years (B), and 4 years (C) of
ociation between observed and expected percents is plotted as a solid line,
riates
95% CI p Value Wald Chi-Square
2.20–2.47 0.0001 831.7
465.9
1.62–1.79 0.0001
1.61–1.80 0.0001 355.2
1.36–1.50 0.0001 190.6
149.3
1.29–1.42 0.0001
83.2
1.20–1.33 0.0001
1.19–1.33 0.0001 69.9ion P
of risk
ar ass
.Cova
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of risk at the 3 different follow-up time points of 2, 3, and
4 years. The plots demonstrate that the models are very well
calibrated across levels of risk with very close agreement
between observed and expected proportions across the full
range of predicted risk. The Hosmer-Lemeshow test statis-
tics for these comparisons demonstrate that small differ-
ences between observed and expected mortality risk in the
context of the large number of patient studied were statis-
tically significant at 2 or 3 years of follow-up (p  0.001)
but not at 4 years of follow-up (p  0.096).
Nomogram. The abbreviated model equation is repre-
sented in the form of a nomogram in Figure 2. The
nomogram can be used to estimate the probability of
survival up to 4 years after ICD implantation for an
individual patient, on the basis of patient-specific values for
the 7 “SHOCKED” covariates: 75 years of age or older,
heart failure (NYHA class III), out of rhythm because of atrial
fibrillation, chronic obstructive pulmonary disease, kidney dis-
ease (chronic), ejection fraction (left ventricular) 20%, and
iabetes mellitus.
The nomogram yields up to 360 total points for patients
n the basis of their combinations of covariate values. The
istribution of the total points obtained using the nomo-
ram for patients in the validation cohort is plotted in
igure 3. Mortality rates on the basis of quintiles of risk
Figure 2 Nomogram for Determination of Survival Probabilities
A nomogram is presented for the estimation of survival 1 to 4 years after implanta
factors from the abbreviated model. To calculate patient survival probabilities, obt
the value of each covariate, calculate the total points obtained from all 7 covariat
ated probability of survival for the patient at the time point of interest after the pro
obstructive pulmonary disease; DM  diabetes mellitus; LVEF  left ventricular ejrom the nomogram-based risk score in the validationohort are shown in Figure 4A. Mortality rates incremen-
ally increase by quintile for all time points. In Figure 4B,
he highest quintile of risk (nomogram score 202) is
ivided into 4 groups in order of ascending risk. As shown,
atients in the highest decile of risk (nomogram score
ICD Implantation
rdioverter-defibrillator (ICD) implantation on the basis of the 7 “SHOCKED” risk
ints for each covariate value by dropping a vertical line from the points axis to
s, and then drop a vertical line from the total points axis to locate the associ-
e. AF  atrial fibrillation; CKD  chronic kidney disease; COPD  chronic
fraction; NYHA  New York Heart Association.
Figure 3 Distribution of the Risk Score in the
Validation Cohort
The frequency distribution of the nomogram-based risk score (derived from the
abbreviated model) is shown. The score ranges from 0 to 360.After
ble ca
ain po
e value
cedur
ection
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44%, and 65%, respectively, while the 5% of patients with
the highest risk (nomogram score268) had mortality rates
at 1, 2, and 3 years of 30%, 47%, and 68%, respectively.
Discussion
We report the development and validation of a practical
measure for estimating the probability of survival 1 to 4
years after ICD implantation for the primary prevention of
SCD. The nomogram uses 7 clinically relevant and easily
assessed covariates. Nomogram scores allow the identifica-
tion of the 10% to 20% of patients with the highest
mortality rates after ICD implantation. The model repre-
sented by the nomogram demonstrates adequate discrimi-
nation, and it closely matches the performance obtained by
a more complete model using many more patient charac-
teristics to estimate survival. The nomogram provides a
practical and easy method for the determination of patient-
Figure 4 Mortality Rates by Quintile of
Risk Score in the Validation Cohort
The mortality rates at 1, 2, and 3 years in the validation cohort on the basis of
quintile of the nomogram-based risk score are shown (A). In addition, mortality
rates are also shown, with the highest quintile split into 4 groups in ascending
order of risk (B). Group 5A represents percentiles 80 to 84, while group 5D
represents percentiles 95 to 99.specific survival probabilities at the bedside.From prior clinical trials (10) and smaller studies (16–18),
common covariates such as age, NYHA class, severe left
ventricular systolic dysfunction, renal insufficiency, and atrial
fibrillation have emerged as predictors of increased risk. Other
studies have reported risk scores for prediction of total mortal-
ity in patients presumed to be at risk for SCD but not
necessarily receiving ICDs on the basis of current practice
guidelines (19,20). Another more complex construct based on
a clinical trial population has also been described (6).
Although there are some advantages of analyzing data
from randomized trials, the predominant disadvantage is
that these patients are highly selected and not necessarily
representative of patients in real-world practice. For exam-
ple, the mortality rate in the combined development and
validation cohorts over a median follow-up of 4 years was
significantly higher than the 4-year mortality rate in patients
who received ICDs in SCD-HeFT (32% vs. 22%, p 
0.001) (3). In addition, patients in this Medicare-based
population were on average 8 to 12 years older than patients
in major clinical trials and 4 years older than patients in the
American College of Cardiology’s National Cardiovascular
Data Registry ICD Registry as a whole (21); 40% of these
Medicare beneficiaries were 75 years of age or older. These
demographics may be more typical of patients with heart
failure meeting guideline-based criteria for ICDs in clinical
practice in both the United States and other countries (22).
Medicare beneficiaries receive the majority of ICDs in
the United States (21). On the basis of data from two large
and distinct cohorts comprising more than 45,000 patients,
the present risk assessment model provides an accurate
picture of how we can best identify the 10% to 20% of
patients with the highest expected mortality rates soon after
ICD implantation in the real-world setting. Interestingly,
analyses of the 2 major ICD trials (2,3) that have formed the
basis for current implantation guidelines both found that
the 19% to 20% of patients with the highest predicted
mortality rates after ICD implantation did not derive a
survival benefit from ICD implantation (albeit with a
somewhat broad confidence interval in 1 of the analyses)
(6,10). With this in mind, it is compelling, for example, that
the 3-year mortality rate for registry patients in the highest
nomogram-based quintile of risk (58%) was even higher
than the 3-year mortality rate for ICD patients in the
highest risk quintile (42%) from the SCD-HeFT analysis
(p  0.001) (6).
Considering the costs and complication rates associated
with the ICD procedure (8,21,23) and the need for frequent
follow-up in patients with ICDs, these findings have im-
portant implications for health care systems and patients.
Patients eligible for primary prevention ICDs tend to
overestimate their own likelihood of survival and have a
poor understanding of the risks and benefits associated with
ICDs (24). Furthermore, guidelines have been carefully
designed to give clinicians the flexibility to offer patients
individualized care (11). The findings of our study are
11
1
1655JACC Vol. 60, No. 17, 2012 Bilchick et al.
October 23, 2012:1647–55 Mortality After ICDs in Clinical Practicedesigned to provide additional information when counseling
patients who are eligible for primary prevention ICDs.
Study limitations. First, it is important to point out that the
aim of our study was to assess the risk for all-cause mortality in
patients undergoing primary prevention ICD implantation.
Although this was not a randomized clinical trial with a
placebo group for comparison, this analysis included a very
large number of patients, which allowed us to closely analyze a
larger number of clinical factors in predicting poor survival
early after ICD implantation. Second, we included only vari-
ables measured at the time of ICD implantation and, as a
consequence, did not account for risk factors that could have
developed over time; however, the goal of risk assessment is to
assess prognosis on the basis of baseline parameters. Third, our
study focused on identifying the effects of high-risk patient
characteristics on mortality after ICD implantation only. Pa-
tients with low-risk characteristics may also not benefit from
ICD implantation, as shown in the MADIT II analysis (10).
Conclusions
We present a practical method for estimating the probability of
survival from 1 to 4 years after ICD implantation for the
primary prevention of SCD. The nomogram uses patient-
specific values for 7 key risk factors assessed for Medicare
beneficiaries who receive the majority of ICD implants in the
United States. These findings have been derived and externally
validated using data from more than 45,000 patients. This
method for estimating the probability of survival could improve
clinical decision making for this patient population by provid-
ing clinicians with a well-validated and practical method for
predicting survival for real-world patients undergoing ICD
implantation for the primary prevention of SCD.
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